Literature DB >> 35166156

Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients.

David Garcia-Azorin1, Almudena Layos-Romero2, Jesús Porta-Etessam3,4,5, Javier A Membrilla6,7, Edoardo Caronna8,9, Alicia Gonzalez-Martinez10, Álvaro Sierra Mencia1, Tomás Segura2, Nuria Gonzalez-García3,4,5, Javier Díaz-de-Terán6,7, Victor J Gallardo9, Ana Beatriz Gago-Veiga10, Alejandro Ballvé8, Javier Trigo López1, María Sastre-Real6,7, Arnau Llauradó8, Ana Cornejo11, Íñigo de Lorenzo6,7, Ángel Guerrero-Peral1,12, Patricia Pozo-Rosich8,9.   

Abstract

BACKGROUND: Headache is a frequent symptoms of coronavirus disease 2019 (COVID-19). Its long-term evolution remains unknown. We aim to evaluate the long-term duration of headache in patients that presented headache during the acute phase of COVID-19.
METHODS: This is a post-hoc multicenter ambisective study including patients from six different third-level hospitals between 1 March and 27 April 2020. Patients completed 9 months of neurological follow-up.
RESULTS: We included 905 patients. Their median age was 51 (IQR 45-65), 66.5% were female, and 52.7% had a prior history of primary headache. The median duration of headache was 14 (6-39) days; however, the headache persisted after 3 months in 19.0% (95% CI: 16.5-21.8%) and after 9 months in 16.0% (95% confidence interval: 13.7-18.7%). Headache intensity during the acute phase was associated with a more prolonged duration of headache (Hazard ratio 0.655; 95% confidence interval: 0.582-0.737).
CONCLUSION: The median duration of headache was 2 weeks, but in approximately a fifth of patients it became persistent and followed a chronic daily pattern.

Entities:  

Keywords:  COVID-19; Headache disorders; migraine; post-COVID; secondary

Mesh:

Year:  2022        PMID: 35166156     DOI: 10.1177/03331024211068074

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.075


  9 in total

Review 1.  COVID-19 2022 update: transition of the pandemic to the endemic phase.

Authors:  Michela Biancolella; Vito Luigi Colona; Giuseppe Novelli; Juergen K V Reichardt; Ruty Mehrian-Shai; Jessica Lee Watt; Lucio Luzzatto
Journal:  Hum Genomics       Date:  2022-06-01       Impact factor: 6.481

2.  Cardio-Pulmonary Dysfunction Evaluation in Patients with Persistent Post-COVID-19 Headache.

Authors:  Álvaro Aparisi; Cristina Ybarra-Falcón; Carolina Iglesias-Echeverría; Mario García-Gómez; Marta Marcos-Mangas; Gonzalo Valle-Peñacoba; Manuel Carrasco-Moraleja; César Fernández-de-Las-Peñas; Ángel L Guerrero; David García-Azorín
Journal:  Int J Environ Res Public Health       Date:  2022-03-26       Impact factor: 3.390

Review 3.  Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management.

Authors:  Pedro Augusto Sampaio Rocha-Filho
Journal:  Headache       Date:  2022-05-11       Impact factor: 5.311

4.  A bibliometric analysis of COVID-19 publications in neurology by using the visual mapping method.

Authors:  Qian Zhang; Jian Li; Ling Weng
Journal:  Front Public Health       Date:  2022-07-26

5.  Therapeutic Approaches to the Neurologic Manifestations of COVID-19.

Authors:  Edith L Graham; Igor J Koralnik; Eric M Liotta
Journal:  Neurotherapeutics       Date:  2022-07-21       Impact factor: 6.088

6.  Protracted headache after COVID-19: A case series of 31 patients from a tertiary headache center.

Authors:  Leon S Moskatel; Liza Smirnoff
Journal:  Headache       Date:  2022-06-07       Impact factor: 5.311

Review 7.  Long COVID headache.

Authors:  Claudio Tana; Enrico Bentivegna; Soo-Jin Cho; Andrea M Harriott; David García-Azorín; Alejandro Labastida-Ramirez; Raffaele Ornello; Bianca Raffaelli; Eloísa Rubio Beltrán; Ruth Ruscheweyh; Paolo Martelletti
Journal:  J Headache Pain       Date:  2022-08-01       Impact factor: 8.588

8.  Structural brain changes in patients with persistent headache after COVID-19 resolution.

Authors:  Álvaro Planchuelo-Gómez; David García-Azorín; Ángel L Guerrero; Margarita Rodríguez; Santiago Aja-Fernández; Rodrigo de Luis-García
Journal:  J Neurol       Date:  2022-09-30       Impact factor: 6.682

9.  Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors.

Authors:  Alicia Gonzalez-Martinez; Ángel Luis Guerrero-Peral; Susana Arias-Rivas; Lorenzo Silva; Álvaro Sierra; Ana Beatriz Gago-Veiga; David García-Azorín
Journal:  J Neurol       Date:  2022-07-12       Impact factor: 6.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.